Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 4/20 | 0.41 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.36 |
| ▸ | TNF | P01375 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | UBE2N | P61088 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335568 | 0.85 | JAK2 (0.43) | CXCR2CXCR1NOTUMIRAK4TNF | |
| SCHEMBL1964260 | 0.85 | JAK2 (0.43) | CXCR2CXCR1NOTUMIRAK4TNF | |
| SCHEMBL7920895 | 0.83 | IRAK4 (0.43) | CXCR2CXCR1IRAK4MEN1TTR | |
| SCHEMBL12391599 | 0.83 | HPGD (0.44) | CXCR2CXCR1MEN1KMT2A | |
| SCHEMBL2344279 | 0.78 | EPHX1 (0.47) | MEN1KMT2ANPC1RAB9AUBE2N | |
| SCHEMBL12391596 | 0.78 | EPHX1 (0.47) | MEN1KMT2ANPC1RAB9AUBE2N | |
| SCHEMBL1966247 | 0.78 | EPHX1 (0.47) | MEN1KMT2ANPC1RAB9AUBE2N | |
| SCHEMBL20302207 | 0.75 | KDM4E (0.48) | CXCR2CXCR1NOTUMIRAK4TNF | |
| SCHEMBL20302185 | 0.71 | HCAR3 (0.52) | MEN1KMT2ARAB9A | |
| SCHEMBL12391600 | 0.71 | JAK2 (0.43) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509424-A1 | NOVEL OXADIAZOLE COMPOUNDS | Abbott Laboratories (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207704-A1 | Novel Oxadiazole Compounds | S1PR3, S1PR1, S1PR2 | CXCR2 341/4885CXCR1 144/4885NOTUM 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.